SANUWAVE HEALTH, INC. (OTCMKTS:SNWV) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On March 1, 2019, SANUWAVE Health, Inc. (the “Company”) amended the expiration date of the Class N Warrants and Class O Warrants (the “Warrant Extension”), from March 17, 2019, to June 28, 2019, to be effective on March 1, 2019. The Company sent a letter to the holders of the Class N Warrants and Class O Warrants regarding the Warrant Extension on March 14, 2019 (the “Warrant Extension Letter”). Certain of the Class O Warrants are held by Kevin Richardson, John Nemelka, Alan Rubino, Michael Stolarski, and Maj-Britt Kaltoft, all of whom are members of our Board of Directors. Certain of the Class O Warrants are held by Lisa Sundstrom, Controller and Chief Financial Officer of the Company.
The foregoing is only a brief description of the Warrant Extension Letter, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the full text of the Warrant Extension Letter taken together with the form of Class N Warrant and form of Class O Warrant. The form of the Class N Warrant is filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 9, 2017, the form of the Class O Warrant is filed as Exhibit 4.1 to this Current Report on Form 8-K filed and the Warrant Extension Letter is filed as Exhibit 4.2 to this Current Report on Form 8-K, and each is incorporated herein by reference.
Item 1.01. Financial Statements and Exhibits
Exhibit No. Description
Form of Class O Warrant.
Letter to Class N Warrant holders and Class O Warrant holders, dated March 14, 2019.
SANUWAVE Health, Inc. Exhibit
EX-4.1 2 snwv_ex41.htm INSTRUMENTS DEFINING THE RIGHTS OF SECURITY HOLDERS,…
To view the full exhibit click
About SANUWAVE HEALTH, INC. (OTCMKTS:SNWV)
SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.